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Background: Septic shock is common and has unacceptably high morbidity, mortality, and associated cost with
numerous failed attempts at developing effective therapies. Endotoxin, one of the most potent mediators of sepsis,
is found in high levels in approximately 50% of patients with septic shock. Polymyxin B (PMX) hemoperfusion has
been shown in numerous studies to successfully remove endotoxin and potentially improve outcomes. EUPHRATES
(Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for
Endotoxemia and Septic shock) is a theragnostic trial (matching blood measurement to treatment capability) of
PMX hemoperfusion in patients with septic shock and confirmed endotoxemia as measured by the endotoxin
activity assay (EAA).
Methods: EUPHRATES is a pivotal regulatory trial that is multi-centered, placebo-controlled and blinded. The trial is
being conducted in fifty ICUs in the United States and Canada and is powered to enroll 360 patients. Patients with
persistent septic shock despite adequate fluid resuscitation on vasopressors for more than 2 and less than 30 hours
are eligible for measurement of the EAA. Those with EAA ≥0.60 are eligible to be randomized to treatment with
two sessions of PMX hemoperfusion 24 hours apart. The primary endpoint for the trial is 28-day all-cause mortality.
Discussion: Unique features of the trial include absence of systemic inflammatory response (SIRS) criteria as a
requirement for inclusion, use of the EAA to confirm endotoxemia as a requisite for treatment, and use of a
detailed “façade” hemoperfusion event as a blinding mechanism. The outcomes of the second interim analysis
included a resizing of the trial to 650 patients and the addition of an exclusion criterion of subjects with multiple
organ dysfunction score (MODS) ≤ 9. Results are anticipated in 2016.
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Despite great advances in our understanding of the
pathophysiology of severe sepsis (sepsis associated with
organ dysfunction) and septic shock (severe sepsis as-
sociated with need for vasopressors following adequate
fluid resuscitation), attempts to translate these findings
into novel treatments and improved outcomes for pa-
tients have been disappointing [1]. Mortality, morbidity,
and costs associated with management of septic shock pa-
tients in ICUs are unacceptably high [2]. Even the most
promising of potential new therapies targeting specific
mediators of the host response have failed to demonstrate
consistent benefit when tested in large multi-centered,
randomized, controlled trials despite encouraging results
in animals and earlier phase studies [3]. Reasons cited for
these failures are wide ranging, but likely include poor pa-
tient selection for therapies due to the heterogeneous and
syndromic definition of the disease state of sepsis using
American College of Chest Physicians / Society of Critical
Care Medicine consensus criteria as well as failure of these
therapies when subjected to the design rigors and man-
dated mortality outcomes found in late phase regulatory
pathway trials [4].
Endotoxin (lipopolysaccharide; LPS) is perhaps the
best studied and one of the most potent initiators and
mediators of the host response in sepsis. Studies measur-
ing endotoxin levels in septic patients have consistently
demonstrated three key findings. First, a dose-response
relationship between endotoxin levels in septic patients
and adverse outcomes including organ failure and death
[5]; second, the presence of elevated levels of circulating
endotoxin in some, but not all, patients with sepsis in-
cluding some with Gram positive infections and other
forms of sepsis likely through the mechanism of gut
translocation [5,6]; and third, the persistence of endotox-
emia often days into the course of the disease process of
severe sepsis [7]. A variety of approaches have been tried
to target endotoxin therapeutically including monoclonal
antibodies to neutralize LPS, small molecule and other
competitive inhibitors of the LPS receptor Toll-like re-
ceptor (TLR)4 to block LPS signaling, use of specific
molecules to enhance endotoxin deactivation and clear-
ance, and extracorporeal devices to remove endotoxin
[8]. In 1982, Ziegler and colleagues [9] first reported the
successful treatment of a cohort of patients with Gram
negative bacteremia and shock using a human anti-
serum raised against the Eschericia Coli J5 bacterium
core LPS or endotoxin. A 17% absolute reduction in
death was observed in a selected group of 212 patients
[9]. Of note, a very high percentage of these subjects had
Gram negative bacteremia (63%), anticipated to correlate
very highly with the presence of endotoxemia. Subse-
quently, two large projects both testing monoclonal anti-
bodies targeting LPS in sepsis, HA-1A and E5, eachdemonstrated positive results in early phase studies
[10,11] including a 1991 Ziegler and colleagues study
[11] again demonstrating a 19% reduction in mortality
in the subset of 200 patients with Gram negative
bacteremia treated with HA-1A in a total sample of
543 patients. However, several large follow-up random-
ized controlled trials with both HA-1A as well as E5
were negative and neither drug was approved for clin-
ical use in the United States [12,13]. More recently,
additional attempts at neutralizing endotoxin to in-
crease survival in severe sepsis utilizing (a) bactericidal/
permeability-increasing protein, (b) a lipid emulsion of
recombinant HDL that binds endotoxin, (c) a small
molecule TLR4 inhibitor (TAK242), and (d) E5564, a
lipid A analogue and competitive inhibitor of TLR4,
also all failed to show reduction in mortality in severe
sepsis patients [14-16].
Polymyxin B (PMX) is a cyclic cationic polypeptide
antibiotic derived from Bacillus polymyxa that has the
ability to bind and neutralize endotoxin. Unfortunately,
infusion of polymyxin in humans results in nephrotox-
icity and neurotoxicity limiting its intravenous use to
salvage therapy for Gram negative enterobacteriaciae re-
sistant to other antibiotics [17]. A novel therapeutic
strategy whereby PMX is adsorbed to a polystyrene fiber
in a hemoperfusion device that is used to remove circu-
lating endotoxin was developed in Japan in the late
1990s. A wide variety of small open-label clinical trials
using this strategy in sepsis and other patient subtypes
have been published with generally encouraging results.
Cruz and colleagues [18] published a systematic review
and meta-analysis of 28 trials using PMX direct hemo-
perfusion (PMX-DHP) to treat patients with severe sep-
sis and septic shock. Although there was heterogeneity
amongst the trials largely done in Europe and Japan,
across a total cohort of 978 patients treated with the
therapy, improvements were noted in hemodynamics
(mean arterial pressure) as well as oxygenation (PaO2/
FiO2 ratio, and there was a statistically significant im-
provement in risk of death (risk ratio 0.53, 95% CI 0.43
to 0.65) [18]. More recently, in 2009, the Early Use of
Polymyxin Hemoperfusion in Abdominal Septic Shock
(EUPHAS) trial [19], a randomized but unblinded study
of 64 patients in 10 tertiary Italian ICUs, demonstrated
statistically significant improvements in the primary end-
points of hemodynamics and organ dysfunction. Also, the
absolute risk of death at 28 days improved significantly
from 53% in the conventional therapy group to 32% in the
PMX-DHP treated group [19]. This result, albeit encour-
aging, is considered controversial as the trial was stopped
early after an interim analysis showed the mortality differ-
ence in a secondary endpoint. In addition, the trial was
not blinded [20]. Patients were selected for therapy based
on evidence of septic shock from an intra-abdominal
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endotoxin levels were not measured prior to enrollment -
a common theme in all the previously discussed trials
attempting to neutralize endotoxin with drug therapy.
Thus, there have been widespread calls for a definitive
randomized controlled trial on this promising but not
widely accepted therapy in North America [20].
Here, we present the protocol for, and discuss the de-
sign, of the “Evaluating the Use of Polymyxin B Hemoper-
fusion in a Randomized controlled trial of Adults Treated
for Endotoxemia and Septic shock (EUPHRATES)” trial.
We believe it to be the first blinded and randomized con-
trolled, diagnostic-directed trial of a hemoperfusion device
ever done in sepsis. We hypothesize that targeted treat-
ment of patients with septic shock and high levels of cir-
culating endotoxin as confirmed by the endotoxin activity
assay (EAA) combined with directed therapy in the form
of PMX-DHP endotoxin removal, will result in a signifi-
cant reduction in 28-day all-cause risk of death.
Methods and design
Study design and outcomes
The ongoing EUPHRATES trial (Clinicaltrials.gov identi-
fier: NCT01046669) is a North American pivotal (under
Investigational Device Exemption (IDE) from the United
States Food and Drug Administration (FDA)) double-
blinded theragnostic trial of PMX-DHP therapy in adult
patients with septic shock and confirmed endotoxemia
as measured by EAA. The trial began in June 2010 and
is scheduled to be completed by the end of 2016. Ethics
approval for the trial protocol has been obtained from
the research ethics board responsible for each site prior
to starting the trial. A list of all ethical bodies that
reviewed and approved the trial is listed in Table 1. The
primary outcome of the trial is 28-day all-cause mortal-
ity. The total number of patients estimated to be in-
cluded in the study was planned as 360 from 50 ICUs in
the United States and Canada. Consecutive patients with
evidence of septic shock as indicated by initiation of
intravenous antibiotics and on vasopressor therapy for
hypotension will be screened and those eligible will be
consented for a blood draw for measurement of EAA.
The consort diagram is shown in Figure 1. Those with
an EAA ≥0.60 (high endotoxin activity level) will be con-
sidered eligible and consented for randomization to po-
tential treatment with PMX-DHP or the control group.
Otherwise, eligible patients with an EAA <0.60 after up
to two blood draws 4 to 6 hours apart will be not be ran-
domized but will be followed using a minimal dataset
for mortality at 28 days in an observational cohort study.
It is estimated that approximately 50% of otherwise eli-
gible patients will have an EAA ≥0.60. Table 2 summarizes
the inclusion and exclusion criteria for EUPHRATES.
Note that a patient with any type of infection producingseptic shock is eligible to be enrolled if high endotoxin ac-
tivity is present (EAA ≥0.60) as endotoxemia is not limited
to Gram negative infection only (likely gut-derived endo-
toxin from translocation in non-Gram negative bacterial
shock). In addition to the primary outcome measure of
28-day all-cause mortality, secondary outcomes include 90-
day, 6-month and 1-year all-cause mortality. Hemodynamic
outcomes will be followed using the cumulative vasopres-
sor index (Table 3) and other organ failure outcomes will
be captured as both total and component scores of the
multiple organ dysfunction score (MODS) [21,22]. Renal
outcomes will be tracked using the Acute Kidney Injury
(AKIN) criteria [23]. A full list of secondary and explora-
tory objectives is listed in Table 4.
Participants
Participants aged ≥18 years old with septic shock and
high endotoxin activity (EAA ≥0.60) are eligible for the
study. Written informed consent is obtained from each
patient or their substitute decision maker prior to
randomization. Septic shock is defined as a docu-
mented or suspected infection as indicated by either
directed or empiric use of antibiotics and presence of
hypotension of at least 2 hours duration requiring on-
going vasopressor support despite a fluid challenge of
30 ml/kg in the previous 24 hours. Subjects must also
have at least one additional organ failure as defined by
oliguria, thrombocytopenia, or need for mechanical venti-
lation. There is no requirement for subjects to meet any
systemic inflammatory response syndrome criteria. Sub-
jects with end-stage renal disease on dialysis are not eli-
gible. The estimated 28-day mortality in this cohort of
patients as per the Surviving Sepsis Campaign (SSC) data-
base estimate is 35% [24].
Investigators agree to managing patients in line with
the SSC guidelines [25,26]. There are no specific man-
agement requirements; however, as indicators of overall
adherence to SSC guidelines and good clinical practices,
two quality measures are being monitored.
Study procedures
Coordination and randomization
A clinical coordinating center (C4) at Cooper University
Hospital, Camden, NJ, USA, has been established to
confirm subject eligibility for the study and provide sup-
port to investigators and study personnel throughout the
study period. The C4 consists of four members to evalu-
ate eligibility (sepsis members) and two nephrologists
(nephrology members) who provide treatment-related
support. Subjects approved for randomization based on
meeting full eligibility criteria including an EAA ≥0.60
will be randomized. Randomization will be 1:1 using
random block sizes of two and four. Research pharmacists
will dispense identical boxes containing either treatment
Table 1 Institutional Review Board information for EUPHRATES
SDI-PMX-NA001 (EUPHRATES) site IRB list
Site# IRB Chair IRB address Approval date
Site #01 Louis Zeiger, MD Cooper Health System 18 Mar 2010
Institutional Review Board
Three Cooper Plaza Suite 504 Camden, NJ 08103
Site #02 Theodore D Schultz Western Institutional Review Board 12 Jul 2010
3535 Seventh Ave. SW
Olympia, WA 98502
Site #04 (site closed) James Linakis Lifespan Office Research Administration Committee
on the Protection of Human Subjects
17 Sep 2010
Rhode Island Hospital Institutional Review Board
593 Eddy St – Aldrich, 5 Providence, Rhode Island
02903
Site #05 William Tremaine Institutional Review Board 04 Mar 2011
Office for Human Research Protection
201 Building, Room 4–60
200 First Street S.W.
Rochester, Minnesota 55905
Site #06 Anne Dougherty, MD The Committee for the Protection of Human
Subjects
21 Dec 2010
6410 Fannin St., Suite 1100
Houston, TX 77030
Site #07 Donald York, PhD Institutional Review Board 16 Aug 2010
621 S. New Ballas, Suite 6002
St. Louis, Mo. 63141
Site #08 Theodore D Schultz Western Institutional Review Board 29 Nov 2010
3535 Seventh Ave. SW
Olympia, WA 98502
Site #09 Roger S Wilson, MD Institutional Review Board/Privacy Board (IRB/PB) 14 Dec 2010
Memorial Sloan Kettering Cancer Center
1275 York Avenue
New York, NY 10065
Site #10 Ernest Prentice, PhD Office of Regulatory Affairs 13 Dec 2010
Institutional Review Board
987830 Nebraska Medical Center
Omaha, NE 68198-7830
Site #11 Peter Lichtenthal, MD Human Subjects Protection Program 22 Nov 2010
1618 E. Helen Street
The University of Arizona
PO Box 245137
Tucson, AZ 85724
Site #12 Glenn Markenson,MD and Rick
Granowitz, MD




Site #13 Theodore D Schultz Western Institutional Review Board 24 Nov 2010
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Table 1 Institutional Review Board information for EUPHRATES (Continued)
3535 Seventh Ave. SW
Olympia, WA 98502
Site #16 Theodore D Schultz Western Institutional Review Board 04 April 2011
3535 Seventh Ave. SW
Olympia, WA 98502
Site #17 (site closed) Theodore D Schultz Western Institutional Review Board 11 Apr 2011
3535 Seventh Ave. SW
Olympia, WA 98502
Site #19 Craig Scoville, MD, PhD Eastern Idaho Regional Medical Center IRB 14 Mar 2011
3100 Channing Way
Idaho Falls, ID 83404
Site #20a and 20b Mike Caligiuri University of California San Diego 27 Oct 2011
9500 Gilman Drive
La Jolla, California 92093
Site #21 Jennifer Weinman, BA, MA Washington University in St. Louis 21Feb 2012
Human Research Protection Office
660 South Euclid Avenue
Campus Box 8089
St. Louis, MO 63110
Site #22 J Bruce Smith, MD, CIP Thomas Jefferson University Hospital 20 Oct 2011
111 S. 11th Street
Philadelphia, PA 19107
Site #23a Theodore D Schultz Western Institutional Review Board 29 Sep 2011
3535 Seventh Ave. SW
Olympia, WA 98502
Site #23b Manoo Bhakta, MD College of Medicine, Chattanooga 5 Jul 2012
Scientific Review Board
960 East Third Street
Suite 102
Chattanooga, TN 37403
Site #25 (site closed) John T Promes, MD Orlando Health 20 Jan 2012
1414 Kuhl Avenue
Orlando, FL 32806
Site #26 SKM Kimber, MD, FRCPC Health Research Ethics Board 9 Jan 2012
308 Campus Towers
University of Alberta
Edmonton, Alberta, Canada T6G 1 KB
Site #27 (site closed) Pamela J Oatis, MD Research Oversight and Education 29 Feb 2012
Mercy St. Vincent Medical Center
2213 Cherry Street
Toledo, OH 43608
Site #28 (site closed) Lois Colliler Sharp Corondado 18 Apr 2012
Sharp Memorial Hospital
5555 Gossmont Center
La Mesa, CA 91942
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Table 1 Institutional Review Board information for EUPHRATES (Continued)
Site #29a Russell Bjork, MD Memorial Health System 27 Mar 2012
1400 East Boulder
Colorado Springs, CO 80909
Site #29b Russell Bjork, MD Memorial Health System 26 Oct 2012
1400 East Boulder
Colorado Springs, CO 80909
Site #30 Philip C Hébert, MD PhD FCFPC Research Ethics Office, Room C819 11 Sep 2012
2075 Bayview Avenue
Toronto, ON Canada M4N 3 M5
Site #31 JD Miller, MD System Center-Hazard 11 Apr 2012
100 Airport Gardens Road
Hazard, KY 41701
Site #32 Steven Kushner, MD Helen F. Graham Cancer Center & Research Institute 01 Jul 2013
West Pavilion - Suite 2350
4701 Ogletown-Stanton Road
Newark, Delaware 19713




Sites #34a and #34b Vivek Singh, MD Institutional Review Board Office 09 Aug 2012
Mail Code 7830
7703 Floyd Curl Dr.
San Antonio, TX 78229-3900




Ottawa, ON K1Y 4E9
Site #36 Allen Korenbilt, MD, CIP Rush University Medical Center 31 Oct 2012
1653 West Congress Parkway
Chicago, IL 60612-3833
Site #37 Theodore D Schultz Western Institutional Review Board 17 Sep 2012
3535 Seventh Ave. SW
Olympia, WA 98502
Site #38 Theodore D Schultz Western Institutional Review Board 24 Jan 2013
3535 Seventh Ave. SW
Olympia, WA 98502
Site #39 Leonardo Tamariz, MD, MPH Human Studies Subcommittee 19 Sep 2012
Miami VA Healthcare System
1201 Northwest 16th St.
Miami, FL 33125-1693
Site #40 Theodore D Schultz Western Institutional Review Board 17 Jan 2013
3535 Seventh Ave. SW
Olympia, WA 98502
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Table 1 Institutional Review Board information for EUPHRATES (Continued)
Site #42 Jeffrey Silverstein, MD, CIP; Icahn School of Medicine at Mount Sinai 01 Feb 2013
Glenn Martin, MD, CIP; One Gustave L. Levy Place
Ilene Wilets, PhD, CIP Box 1081
New York, NY 10029-6574
Site #43 John Montogomery, Chair Lakeridge Health 04 Apr 2013
1 Hospital Ct.
Oshawa, ON, Canada L1G 2B9
Site #44 SKM Kimber, MD, FRCPC 308 Campus Tower 27 Feb 2013
University of Alberta
Edmonton, AB T6G 1 K8
Site #45 Franck Molin, MD IUCPQ 15 Apr 2013
2725, Chemin Sainte-Foy
Quebec, QC G1V 4G5
Site #46 Alan Lichtin Cleveland Clinic Foundation 05 Mar 2013
9500 Euclid Ave.
Cleveland, OH 44195
Site #48 Timothy Roehrs, PhD Henry Ford Health System Research Administration 01 Apr2013
2799 West Grand Blvd
CFP-bsmt, room 46
Detroit, MI 48202
Site #49 Stacey A. Page, PhD, Chair, CHREB Conjoint Health Research Ethics Board (CHREB) 10 Sep 2013
Research Services Office
3rd Floor Mackimmie Library Tower (MLT 300)
2500 University Dr., NW
Calgary, AB, Canada T2N 1 N4




Toronto, ON, Canada M5G 1X5
Site #52a and #52b Karen McRae, MD, Co-Chair/Multidisciplinary
UHN REB
University Health Network (UHN) 15 Apr 2013
Research Ethics Board (REB)
10th Floor, Room 1056
700 University Ave.
Toronto, ON, Canada M5G 1Z5
Site #53 R Bert Wilkins Western Institutional Review Board 22 Jul 2013
3535 Seventh Ave. SW
Olympia, WA 98502
Site #54 L Wiley Nifong, MD UMCIRB 12 Feb 2014
East Carolina University
Brody School of Medicine, Brody 4 N-70
Greenville, NC 27834
Site #55 Rhodes L Rigsby, MD Institutional Review Board 05 Sep 2013
Research Protection Programs
24887 Taylor St.
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Table 1 Institutional Review Board information for EUPHRATES (Continued)
Suite 202
Loma Linda, CA 92350
Site #56 David Spiegel, MD Stanford University Research 12 Jun 2012
Compliance Office
1501 South California Ave.
MC: 5579
Palo Alto, CA 94304
Site #57 Ike Eriator, MD University of Mississippi Medical Center 12 Feb 2013
Institutional Review Board
2500 North State St.
Jackson, MS 39216-4505
Site #58 Michael Geisser, PhD, Co-Chair University of Michigan, IRBMED 7 Mar 2014
2800 Plymouth Road
Building 520, Room 3214
Ann Arbor, MI 48109-2800
Klein et al. Trials 2014, 15:218 Page 8 of 15
http://www.trialsjournal.com/content/15/1/218cartridge boxes or sham boxes based on a serial number
code linked to the randomization scheme. The sepsis C4
members are blinded to treatment allocation while the
nephrology C4 team can be unblinded as needed.
Timing
To be eligible for treatment, following a minimum fluid
challenge, patients must be in septic shock and on vaso-
pressors at the specified dose levels in Table 2 for at least
2 hours continuously and not for more than 30 hours. A
sample timeline for consent, measurement of EAA, and
randomization are shown in Figure 2. The first treatment
must be initiated within 24 hours of the EAA consent and
the second approximately 22 hours after the first treat-
ment. A sample timeline for the intervention period is
shown in Figure 3.Figure 1 Consort diagram for EUPHRATES (Evaluating the Use of Poly
Adults Treated for Endotoxemia and Septic shock trial). EAA, endotoxiMeasurement of endotoxin activity assay
The EAA received 510(k) de novo clearance from the
FDA in 2003 for the measurement of clinical samples
for endotoxemia and to assess patients for risk of severe
sepsis. The assay is semi-quantitative and values are
expressed as EAA units between 0 and 1. A low EAA
level is considered to be <0.40, intermediate level 0.40 to
0.59, and high level ≥0.60 (Spectral Diagnostics Inc.,
Toronto, Ontario, Canada). These cutoffs were established
based on the results of the MEDIC trial [5]. The details
of how to perform the assay are published elsewhere
[27]. In the current trial, samples are run in duplicate by
trained personnel. A correlation value of 15% or better
is required for EAA results less than <0.20, and 20% for
all other EAA results. If a patient is otherwise eligible but
the EAA is below the high threshold of 0.60, a follow-upmyxin B Hemoperfusion in a Randomized controlled trial of
n activity assay.
Table 2 Summary of inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Subjects who meet the following criteria (and have a signed informed
consent) will be allowed into the study:
1. Inability to obtain an informed consent from the subject, family
member or an authorized surrogate
1. Age ≥18 years of age 2. Lack of commitment for full medical support
2. Hypotension requiring vasopressor support: Requirement for at least
one of the vasopressors listed below, at the dose shown below, for at
least 2 continuous hours and no more than 30 hours
3. Inability to achieve or maintain a minimum mean arterial pressure
of ≥65 mmHg despite vasopressor therapy and fluid resuscitation
a. Norepinephrine >0.05 μg/kg/minute 4. Subject has end-stage renal disease and requires chronic dialysis
b. Dopamine >10 μg/kg/minute 5. There is clinical support for non-septic shock such as
c. Phenylephrine >0.4 μg/kg/minute a. Acute pulmonary embolus
d. Epinephrine >0.05 μg/kg/minute b. Transfusion reaction
e. Vasopressin >0.03 units/minute c. Severe congestive heart failure (for example, New York Heart
Association Class IV, ejection fraction <35%)
f. Vasopressin (any dose) in combination with another vasopressor listed
above
6. Subject has had chest compressions as part of cardiopulmonary
resuscitation this hospitalization without immediate return to
communicative state
3. The subject must have received intravenous fluid resuscitation of a
minimum 30 mL/kg administered within 24 hours of eligibility
4. Documented or suspected infection defined as definitive or empiric
intravenous antibiotic administration
7. Subject has had an acute myocardial infarction within the past 4 weeks
5. Endotoxin activity assay ≥0.60 8. Subject has uncontrolled hemorrhage (acute blood loss requiring >3
Units of Packed red blood cellsin the past 24 hours)
6. Evidence of at least one of the following criteria for new onset organ
dysfunction that is considered to be due to the acute illness
9. Major trauma within 36 hours of screening
a. Requirement for positive pressure ventilation via an endotracheal tube
or tracheostomy tube
10. Subject has severe granulocytopenia (leukocyte count <500 cells/mm3)
or severe thrombocytopenia (platelet count <30,000 cells/mm3)
b. Thrombocytopenia defined as acute onset of platelet count <150,000 μ/L
or a reduction of 50% from prior known levels
11. HIV infection in association with a last known or suspected CD4 count
of <50/mm3
c. Acute oliguria defined as urine output <0.5 ml/kg/hour for at least
6 hours despite adequate fluid resuscitation
12. Subject’s baseline state is non-communicative
13. Subject has sustained extensive third-degree burns within the past
7 days
14. Body weight <35 kg
15. Known hypersensitivity to polymyxin B
16. Subject has known sensitivity or allergy to heparin or has a history of
heparin associated thrombocytopenia
17. Subject is currently enrolled in an investigational drug or device trial
18. Subject has been previously enrolled in the current trial
19. Any other condition, that in the opinion of the investigator, would
preclude the subject from being a suitable candidate for enrolment, such
as end stage chronic illness with no reasonable expectation of survival to
hospital discharge
20. Multiple Organ Dysfunction Score ≤9 ** - added post-second interim
analysis
Klein et al. Trials 2014, 15:218 Page 9 of 15
http://www.trialsjournal.com/content/15/1/218test may be done once, 4 to 6 hours after the first test, to
reassess for potential eligibility.
Description of the study intervention
Patients assigned to the treatment arm who do not
already have access for dialysis will have a standard
hemodialysis catheter inserted in one of the femoral
veins by an unblinded physician not involved in the clin-
ical care of the patient. For those patients not assignedto the treatment arm, a “cut” hemodialysis catheter and
associated dressing will be affixed to the skin in the fem-
oral position to simulate a newly inserted line. The same
physician that would have inserted the catheter stays in
the room behind a curtain for a similar amount of time
as would have been predicted for catheter insertion. At
the conclusion of each hemoperfusion session, a standard
opaque dressing will be placed over the line site to main-
tain the blind. After the second hemoperfusion session,
Table 3 Cumulative vasopressor index
Vasopressor Dose
Range
Dose Range Dose Range Dose
Range
1 point 2 Points 3 Points 4 Points
Dopamine 0 dose ≤ 5 5 < dose ≤ 10 10 < dose ≤ 15 > 15
(mcg/kg/min)
Epinephrine - 0 < dose < 0.05 0.05 < dose < 0.1 > 0.1
(mcg/kg/min)
Norepinephrine - 0 < dose < 0.05 0.05 < dose < 0.1 > 0.1
(mcg/kg/min)
Phenylephrine - 0 < dose < 0.4 0.4 < dose < 0.8 > 0.8
(mcg/kg/min)
Vasopressin - - - Any
dose
(units/min)
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opaque dressing applied over the region. In some pa-
tients the decision for dialysis has been made contem-
poraneously with the consent for study and in that
case a dialysis catheter will be inserted and the treat-
ment blinded only.
The PMX hemoperfusion column used in the study
was developed in Japan and is manufactured by Toray
Industries (Tokyo, Japan). The PMX treatment will be
administered twice using two cartridges with the treat-
ments completed approximately 24 hours apart. Each
treatment will last for approximately 2 hours, at a blood
flow rate of approximately 100 ml/minute through the
circuit (range of 80 to 120 ml/minute). For the current
trial, a standard intermittent hemodialysis machine willTable 4 Secondary and exploratory outcomes
1. To compare mortality between the two groups at 90 days, 6 months an
2. To compare the change in endotoxin levels between the PMX cartridge
second PMX cartridge, with a treatment target of ≥15% reduction of EA
3. To compare the changes in vasopressor doses for the two groups from
4. To compare the number of days of need for vasopressors in each group
5. To compare changes in mean arterial blood pressure for the two group
6. Comparison of the changes in renal function from day 0 to day 3:
i. Fluid balance including urine output
ii. Serum creatinine
7. To compare the effects of two uses of the PMX cartridge on progression
dysfunction score from day 0 to day 3
8. To compare the number of days of need for renal replacement therapy
replacement therapy)
9. To compare the number of days of need for mechanical ventilation in e
ventilation)
10. To compare the mean number of days spent in hospital by subjects in e
11. To compare survival time from baseline to death within 28 days and co
12. To compare survival time from baseline to death within 90 days and cobe used as a blood pump to administer the treatment.
At the discretion of the unblinded nephrologist on the
hemoperfusion team, anticoagulation, using intravenous
unfractionated heparin, will be administered to maintain
patency of the circuit for the duration of each 2-hour
treatment. Patients already on anticoagulation for other
indications or those with coagulopathy will not be anti-
coagulated further at the discretion of the nephrologist on
the hemoperfusion team. Citrate anticoagulation is not
allowed as per the recommendations of the manufacturer.
Blinding
The trial is blinded. For those patients assigned to the
control arm, a simulated or “sham” hemoperfusion event
is carried out to coincide with the timing of the treat-
ment events in the other arm. In addition, a “cut” line is
placed on the skin to simulate the presence of an in-
dwelling central line. To maintain the trial’s blind, the
ICU physician investigators, those health-care profes-
sionals involved in recording blinded data, and those
who are involved in data analysis, will remain blinded to
allocation of treatment.
A nephrology staff member, the study coordinator, the
ICU bedside nurse, and a pharmacist will know the
treatment allocation and are trained to record allocation
and treatment records (timing of device use) and con-
comitant anti-coagulant medication administered (for
example, heparin) on the source documents and case re-
port forms (CRFs) that will be kept blinded from the
remaining study personnel.
Nephrology staff will be trained to use the PMX cart-
ridge on those subjects randomized to the treatmentd 12 months post-start of treatment
-treated group and the control group at 12 hours after completion of a
A levels with PMX cartridge treatment
day 0 to day 3
from day 0 to day 28 (days alive and off vasopressors)
s from day 0 to day 3
of, and recovery from, organ dysfunction using the multiple organ
in each group from day 0 to day 28 (days alive and off renal
ach group from day 0 to day 28 (days alive and off mechanical
ach group for survivors to day 28
mpare the risk of death between the two study arms
mpare the risk of death between the two study arms
Figure 2 Timing for patient identification and enrollment. EAA, endotoxin activity assay.
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randomized to the control arm by performing the
“sham” perfusion event. Study staff (principal investiga-
tor and other ICU personnel involved in the subjects
care) and the subject (and/or the subjects surrogate) will
remain blinded to the study allocation. Pre-treatment
EAA results will be made available to the treating phys-
ician, but all subsequent EAA results are blinded. During
the period of time of the treatment intervention or sham
perfusion event sites employ a number of methods to
ensure the blind is maintained. During the treatment
phase, a façade perfusion event is conducted whereby a
dialysis instrument is brought to the patient’s bedside
and curtains are drawn. A sign is attached to the curtain
indicating that a study procedure is in progress. The un-
blinded nephrology team and/or study coordinator per-
form the hemoperfusion or sham perfusion for
approximately 2 hours. This process is repeated once at
approximately 22 hours such that the treatment of PMX
or sham treatment is completed twice within a 24-hour
period.
Breaks in the blind are reported to the sponsor via the
medical monitor and are recorded in CRFs. Emergency
unblinding procedures include confirmatory correspond-
ence with the pharmacy of the true treatment allocation.Figure 3 Timeline for initiation of intervention. EAA, endotoxin activitySample size and power
The power analysis is based on a two-sided Fisher’s exact
test to compare the proportions of death within or at
28 days between the PMX treatment and control groups.
It is assumed that for the control arm of standard med-
ical care alone approximately 35% subjects will die by
day 28 after the enrollment. It is also hypothesized that
there will be an approximately 15% improvement in 28-day
mortality rate for subjects randomized who receive the
standard medical care plus the PMX cartridge, as compared
to those receiving the standard medical care alone. The
overall significance level for the entire sequence of primary
efficacy tests is assumed at 5% in a two-sided test. An in-
terim analysis based upon safety only was conducted after
76 patients were enrolled in January 2013. No efficacy ana-
lysis was conducted. The data safety monitoring board
(DSMB) noted no specific safety concerns at that time.
There is one planned additional interim analysis approxi-
mately at the midpoint (that is, 180 subjects enrolled). Be-
cause of the planned interim analysis, the maximum
sample size for the trial (that is, if the trial is not ter-
minated by the interim analysis) is based on the final
efficacy test to compare day 28 mortality rate between
the two study arms at a significance level of 0.048
based on the method of O’Brien and Fleming [28].assay.
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study arms, a sample of 180 subjects per study arm (that
is, a total of 360 subjects for both arms) provides at least
80% statistical power to detect the hypothesized effect
size (that is, 15% difference) from the final primary effi-
cacy test. The statistical power with the proposed sample
size will thus be more than 80% from the entire se-
quence of the planned primary efficacy analyses. These
power analyses assume a 15% attrition rate from the ran-
domized subjects of each study arm. Therefore, a mini-
mum of 306 evaluable subjects are necessary to achieve
at least 80% statistical power based on the hypothesized
effect size.
Monitoring
The trial is fully monitored by the contract research
organization responsible for trial operations. A trial
monitoring plan has been established and is on file with
the FDA. One hundred percent source data verification
is done for all data points in the CRFs. Protocol viola-
tions are predefined. Adherence to treatment as defined
by number of treatments delivered versus prescribed as
well as total time of each delivered treatment is compiled
in the CRF and tabulated for analysis. All co-interventions
are captured including concurrent medications. A detailed
policy on co-enrollment in other studies has also been de-
veloped and approved by the DSMB.
Interim analysis
An interim analysis will be performed by an unblinded
statistician independent of the DSMB and the Sponsor
after the first 180 subjects (that is, about 90 per study
arm, or about 50% of the total planned evaluable sub-
jects) complete their day 28 assessment. The interim
analysis will only analyze the portion of the data through
day 28 for subjects who have completed the day 28 as-
sessment and is based on the final efficacy test to com-
pare day 28 mortality rate between the two study arms
at a significance level of 0.048.
The primary purpose of the interim analysis is to de-
termine if the trial should be terminated early or the
study protocol should be modified. The primary popula-
tion for this interim analysis will be the intention to treat
(ITT) population. Secondary analyses will examine the
modified ITT population - that is, all patients who have
at least one treatment application. The issues to be ad-
dressed by the interim analysis will include the possibil-
ity that: (a) the treatment is clearly effective so that it is
unnecessary to continue to the planned termination
point insofar as the primary efficacy endpoint is con-
cerned, P value is less than 0.005; or (b) the treatment is
so ineffective that continuation of the study would pro-
vide little or no chance of ever reaching statistical sig-
nificance. In addition to the efficacy assessment, at theinterim analysis the DSMB will review all serious adverse
events and unanticipated serious device effects to evalu-
ate if there are medically significant justifications due to
excessive side effects or safety concerns to demand an
early end to the trial or a modification of the interven-
tion. The interim analysis will thus evaluate both safety
and efficacy variables.
If the trial is not terminated based on the interim ana-
lysis, the results of the interim efficacy analysis may be
used to revise sample size estimations, which will serve
in planning the remaining part of the trial. An independ-
ent statistician will conduct the power analyses and sam-
ple size re-estimation.
If the trial is terminated as a result of the interim ana-
lysis (that is, P value < 0.005) or by the recommendations
of the DSMB, the final efficacy and safety analyses will
be performed using the entire data of follow-up to
12 months or until the last assessment for all subjects
randomized prior to the study termination date.
Statistical analysis of results
Primary efficacy analyses will be conducted on the ITT
population. The primary efficacy endpoint is the all-
cause mortality rate of the subjects within 28 days after
the initiation of the treatment perfusion or the sham
perfusion. Let P0 and P1 be the proportion of death
within 28 days for the arm of standard medical care
alone and the arm of standard medical care plus the
PMX cartridge, respectively. The primary efficacy ana-
lyses will test the null hypothesis of H0 : P1 = P0 against
the two-sided alternative hypothesis of Ha : P1 ≠ P0. The
test of these hypotheses will be carried out through Fish-
er’s exact test [29]. A two sided 5% significance level will
be assumed for the primary efficacy test. Similar analyses
on the primary efficacy endpoint will also be conducted
on the per protocol population.
In addition, a long-term follow-up of survival status at
90 days, 6 months and 12 months will be undertaken for
the ITT population. This will entail a comparison of sur-
vival rates for ITT subjects at 90 days, 6 months and
12 months after assignment to either the treatment per-
fusion or the sham control perfusion group.
Safety and the data safety monitoring board
An external, independent DSMB was established. The
DSMB acts in an advisory capacity to the Sponsor to
monitor subject safety, including mortality, which is also
the primary efficacy endpoint of the intervention. The
DSMB comprises a group of individuals with a broad
and varied base of pertinent expertise who will review
the accumulating safety data on a quarterly basis. The
DSMB consists of a microbiologist, a nephrologist, a
critical care physician, a biostatistician, and an expert in
clinical trial design. The meetings consist of an open
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sponsor and their representatives from the clinical re-
search organization trial operations team and a closed
session of only DSMB members and one unblinded rep-
resentative from the CRO. The closed session report of
data tables and listings from the database is presented in
a blinded manner. The DSMB has the right to ask for
unblinding any portion of the closed session report if
they deem it necessary. The DSMB will conduct an un-
blinded interim analysis of the safety data when half of
the subjects have completed the first 28 days of the trial.
The DSMB will also provide expert opinion on the clin-
ical relevance of any safety findings, address any safety
issues mentioned by the sponsor and, where applicable
based on the safety data, advise the Sponsor as to the
appropriateness of continuing the trial according to the
protocol or modifying the protocol. The DSMB may ter-
minate the trial if they deem it necessary for the protection
of the safety of potential or current participants.
DSMB members are reimbursed for reasonable ex-
penses related to attending meetings, such as travel
costs, accommodations, and meals. Members are com-
pensated for their time spent performing their responsi-
bilities as members of the DSMB. No other payment or
future consideration is provided. No formal relationship
exists between the DSMB and any other committee in-
volved in the EUPHRATES trial.
Discussion
There are several unique features of the EUPHRATES
trial compared to prior severe sepsis/septic shock stud-
ies. The trial does not include an assessment for features
of the systemic inflammatory response syndrome as part
of standard inclusion criteria. These criteria lack specifi-
city and have been heavily criticized [30]. As an alterna-
tive, EUPHRATES targets patients with persistent shock
and endotoxemia - aligning the purported mechanism of
the treatment effect in hemodynamic improvement and
the treatment of the presumed mediator of the disease
process.
EUPHRATES is the first clinical trial in septic shock
that we are aware of, designed to specifically use a bio-
marker as enrollment criteria for a therapy directed
against that biomarker. This “theragnostic” approach has
already proven successful in disease areas such as cancer
and offers the opportunity to move beyond the con-
straints of the syndrome-based definition of sepsis to
biologically targeted therapy [4,31]. However, this ap-
proach by definition will limit the application of this
therapy to only a part of our existing patient population
with septic shock and endotoxemia, making the need
to search for both new markers and new therapies
even more important for those patients who do not
have endotoxemia. Nevertheless, the approach may be abetter way to conduct sepsis trials using smaller num-
bers of patients with higher efficacy hurdles. In this trial,
if one were to assume that all patients were to be en-
rolled based on meeting clinical criteria alone and that
50% of those patients enrolled were not likely to benefit
from the treatment, a required efficacy hurdle of 7.5%
would be needed or a trial of nearly 1,200 patients. The
duration, cost and complexity of such a trial would likely
be prohibitive.
Finally, EUPHRATES is the first trial of a hemoperfu-
sion device to our knowledge that will be blinded. While
blinding offers significant advantages in the overall
strength of the study, the use of a “sham” perfusion
event rather than true sham perfusion was chosen be-
cause sham perfusion was felt to be unethical and inva-
sive [32]. Blinding a trial of this nature where patients
are unstable and constantly interacting with numerous
health-care providers is challenging and it is our intention
to study the overall strength of the blinding procedures at
the end of this trial so that lessons may be applied to fu-
ture trials of this nature. This will be done by tracking all
unblindings that occur, who was unblinded and how the
unblinding occurred.
Thus, EUPHRATES is a pivotal trial using PMX hemo-
perfusion in patients with septic shock and confirmed
endotoxemia. While the results of recent sepsis trials
have been disappointing, there are several unique fea-
tures of EUPHRATES, including its theragnostic design,
that we hope are a step forward in the design of clinical
trials for this underserved patient population.Trial status
The trial, at the time of submission of this manuscript,
has enrolled approximately 275 subjects with all antici-
pated centers activated and trained. The second interim
analysis was in the first quarter of 2014. Outcomes in-
cluded a positive recommendation to continue the trial,
sample size recalculation to a new total size of 650 pa-
tients, and addition of an exclusion criteria for multiple
organ dysfunction score ≤9.Abbreviations
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